VitaDAO

What VitaDAO does

VitaDAO is a decentralized autonomous organization founded in 2021 that funds early-stage longevity research and incubates biotech startups through community-governed token voting. It serves longevity researchers, biotech companies, and crypto-native contributors by aggregating capital via the VITA governance token and deploying it into aging research through IP-NFTs, equity investments, and grants. The organization has executed approximately $11.2 million in disclosed funding across four rounds, deployed roughly $4.7 million across 31 projects, and reports a treasury exceeding $10 million. Its portfolio includes three operating companies (notably Rubedo Life Sciences, which announced positive Phase 1 results for senescent-cell therapy RLS-1496 in March 2026, and Oisín Biotechnologies, which raised a $15M Series A led by AbbVie Ventures in October 2023), eight clinical-stage drug programs, and eighteen drug discovery programs.

The core technology stack combines on-chain DAO governance and IP-NFT tokenization for fractional ownership of research intellectual property with a suite of AI agents purpose-built for longevity research. The AI agents include AubrAI (a specialist agent live on X providing expert Q&A and study updates), LAIA/Longevist AI (a literature analysis agent in development that curates preprints and generates hypotheses), and the Biohacker Agent (a product development agent in development). The VitaLabs incubator accepts and evaluates research proposals, the token-gated VitaDAO Terminal provides tiered access to scientific insights based on VITA holdings, and the VitaDAO Store sells scientifically-backed longevity supplements (Spermidine & Resveratrol) directly to consumers. Governance occurs on-chain via Snapshot voting and through Discourse-based forums, with smart contracts automating funding flows.

The business model spans multiple revenue mechanics: VITA token-based Terminal subscriptions (recurring), direct-to-consumer supplement e-commerce (one-time), community governance over IP-NFTs and portfolio equity (indirect via token appreciation), and long-tail IP monetization through licensing and equity exits. The go-to-market combines community-led token distribution, event-driven engagement (VitaDAO Symposiums, Vitalia pop-up city in Roatán, Viva Frontier Tower longevity floor in San Francisco, the Longevity Hackers documentary narrated by Edward Norton), and direct pharma partnerships—most notably Pfizer Ventures' $500,000 strategic investment in August 2022, which served as flagship validation of the DeSci funding model. Legal jurisdiction is Switzerland, the organization is GDPR-compliant, and revenue is not publicly disclosed.

Name

VitaDAO

Legal name

VitaDAO

Website

https://vitadao.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

VitaDAO is a decentralized autonomous organization funding early-stage longevity research and incubating biotech startups via token-based community governance. It serves longevity researchers, biotech companies, and crypto-native contributors through IP-NFTs, equity investments, AI research agents, and consumer supplements.

Ownership category

akta.pro rank

Product category

Decentralized Science Funding

NAICS

Software Publishers (513210)

SIC

Finance Services (6199), Security & Commodity Brokers, Dealers, Exchanges & Services (6200)

akta.pro primary industry

Grants, Funding & Budget Allocation Platforms (FSAPAHAE)

akta.pro secondary industries

Coordination & Contributor Management (tasks, bounties, roles) (FSAPAHAD), DAO Treasury, Governance & On-Chain Finance Tools (FSADAMAL)

Keywords

• Decentralized science funding
• Longevity biotech investing
• Blockchain research governance
• IP-NFT tokenization
• DAO research funding

Headquarters

HQ city

Ottawa

HQ country

Canada

HQ region

North America

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. VITA Token Ecosystem: VITA token serves as the governance and utility token of the DAO. Token holders participate in funding decisions, with premium Terminal features unlocked based on token holdings. Token value accrues from the success of funded research projects and IP-NFT appreciation.
2. Longevity Supplement Sales: E-commerce sales of scientifically-proven longevity supplements including Spermidine & Resveratrol products. Revenue from direct consumer sales with 30-day returns policy and international shipping.
3. Research Project Governance: Community members contribute to funding longevity research and receive governance rights over IP-NFTs and equity positions in portfolio companies. Revenue model is indirect through token appreciation and portfolio value.
4. IP Monetization: VitaDAO deploys funding into longevity research and monetizes through IP licensing, equity exits, and IP-NFT trading. The organization has deployed roughly $4 million into longevity research with over $10 million pooled.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Core offering

VitaDAO operates as a decentralized autonomous organization (DAO) that funds and governs early-stage longevity research through community-based token voting. It deploys capital into biotech startups via IP-NFTs and equity investments, curates research with AI agents, and monetizes discoveries through IP licensing. The organization also sells direct-to-consumer longevity supplements (Spermidine & Resveratrol) and offers a token-gated Terminal for premium research access.

Product overview

VitaDAO is a decentralized autonomous organization (DAO) operating as a unified platform for longevity research funding and governance. The ecosystem centers on the VITA governance token and the core VitaDAO Platform, supplemented by VitaLabs (incubator program), the VitaDAO Terminal (tiered-access interface), and an AI agent suite including AubrAI, LAIA, and Biohacker Agent. Additional offerings include the VitaDAO Store (longevity supplements), a Projects Portfolio (funded research), and the Blog/Journal for community updates. The platform funds research through IP-NFTs and equity investments, with governance driven by token holders.

Differentiator

Problem solved

Functional benefit

Brands

• VITA: Governance and utility token for VitaDAO ecosystem
• VitaLabs
• AubrAI
• LAIA (Longevist AI)

Products and services

• VitaDAO Platform Decentralized autonomous organization (DAO) platform that funds and governs longevity research through community token voting, smart contracts, and IP-NFT tokenization. Serves longevity researchers seeking funding, biotech startups seeking capital, and VITA token holders seeking governance participation.
• VITA Token Governance and utility token enabling holders to participate in DAO governance decisions including funding proposals, strategic direction, and protocol upgrades. Higher VITA holdings unlock premium Terminal features.
• VitaLabs Incubator program for early-stage longevity research that accepts applications for funding, supports project evaluation (with LAIA AI assistance), and develops research through VitaDAO's governance process.
• VitaDAO Terminal Premium platform access tiered by VITA token balance, unlocking exclusive scientific insights, advanced terminal features, and research tools for token holders.
• VitaDAO Store (Longevity Supplements) Direct-to-consumer e-commerce store selling scientifically-proven longevity supplements including Spermidine & Resveratrol products in 1-month and 3-month supply options, with international shipping, 30-day returns, and third-party quality testing.
• AubrAI Agent AI agent modeled after Aubrey de Grey that shares RMR2 study updates, answers longevity questions, and provides expert advice to the VitaDAO community via X (Twitter). Connects to X for real-time updates.

Quantifiable outcome

• Rubedo Life Sciences (VitaDAO-backed) achieved positive Phase 1 results for senescent-cell therapy RLS-1496 on March 26, 2026
• +2 more outcomes

Segments3 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• ARTAN BiocoreStrategic or Co-development Partner · 4 June 2026Longevity biotech company based in St. Petersburg, Florida that raised $200,000 through VitaDAO's decentralized science model. The funding advances preclinical development of its engineered suppressor tRNA platform (ARTAN-102) targeting nonsense mutations in aging-related diseases.
• Rubedo Life SciencescoreStrategic or Co-development Partner · 26 March 2026VitaDAO-backed portfolio company that announced positive Phase 1 results for its senescent-cell therapy RLS-1496 on March 26, 2026. This represents VitaDAO's most advanced clinical development program.
• DeSci Sector (KuCoin)minorGTM or Marketing Partner · 14 October 2025VitaDAO ($VITA) is profiled as a top DeSci token by KuCoin, with the DeSci sector collectively exceeding $1 billion market cap. KuCoin provides trading platform access and educational content promoting the sector.
• Laurence Ion (VitaDAO Co-creator)coreOthers · 29 July 2025Co-creator of VitaDAO operates the longevity floor at Viva Frontier Tower in San Francisco, a co-working and co-ideation hub for longevity, AI, crypto, and robotics. The tower hosts robotics and biochemistry labs and longevity conferences.
• Bio ProtocolminorStrategic or Co-development Partner · 1 November 2024DeSci sector collaboration where Bio Protocol ($BIO) token surged 300% monthly, driven partly by partnership with VitaDAO for AI-powered science agent Aubrai. The partnership enables AI-accelerated hypothesis generation and research validation.
• Oisín BiotechnologiescoreStrategic or Co-development Partner · 9 October 2023Multi-asset longevity biotech company pioneering genetic medicines for sarcopenia. VitaDAO provided funding and the company has since raised $15M Series A led by AbbVie Ventures, published preclinical data in Cell Press, and achieved 50% increase in muscle size and 100% increase in strength in treated mice.
• ExcepGen InccoreStrategic or Co-development Partner · 28 June 2023VitaDAO funded ExcepGen Inc as the first company sourced by Pfizer Ventures to be funded by DeSci. The RNA therapeutics company is developing a universal pan-flu vaccine using its RNAx platform, with 400% boost in cargo expression demonstrated in vivo.
• GitcoincoreStrategic or Co-development Partner · 21 November 2021VitaDAO partnered with Gitcoin for quadratic funding rounds to support longevity public goods projects. The collaboration leveraged crypto communities for groundbreaking research funding, with VitaDAO pledging matching funds for curated longevity projects. Vitalik Buterin participated as a donor in these rounds.

Scale indicators13 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Bio Protocol: DeSci platform and $BIO token issuer that has an explicit partnership with VitaDAO for AI-powered science agents (AubrAI). Operates a comparable model of token-governed research funding with multiple DeSci subDAOs.
• Molecule: Web3 biotech IP marketplace and DAO that pioneered the IP-NFT model VitaDAO uses to fund and govern research IP. Closest direct peer in the DeSci space, with overlapping tooling for fractional ownership of scientific IP.
• ValleyDAO: Decentralized autonomous organization funding longevity and age-related disease research using similar IP-NFT and token-governed mechanisms. Directly competitive peer in the DeSci longevity funding niche.
• HairDAO: DeSci DAO funding hair loss research via IP-NFTs and community governance, built on the same Molecule/VitaDAO infrastructure model. Closely comparable structure and mechanism, though narrower therapeutic focus.
• AthenaDAO: DeSci DAO funding women's health and reproductive longevity research using IP-NFTs and token-based governance. Sister DAO in the DeSci collective with a comparable operating model.

Broad incumbents

• Insilico Medicine: AI-driven drug discovery company with a major focus on aging and longevity therapeutics, including clinical-stage programs. Larger, traditional competitor in longevity R&D with overlapping AI-for-drug-discovery approach.
• NewLimit: Well-funded longevity biotech (backed by Brian Armstrong) developing epigenetic reprogramming therapies. Competes for the same high-quality longevity research talent and IP that VitaDAO funds.
• Altos Labs: Ultra-well-capitalized (~$3B raised) cellular rejuvenation biotech focused on aging. Represents the traditional, large-scale end of longevity biotech and a major competitor for top scientific founders.

Others

• Longevity Science Foundation: Non-profit that allocates capital to longevity research projects. Operates as a complementary grantmaking organization with thematic overlap, but uses traditional non-DAO funding mechanisms.
• Decentralized Science Alliance: Industry alliance that promotes and coordinates the DeSci ecosystem of which VitaDAO is a leading member. Not a competitor but a key ecosystem participant supporting VitaDAO's broader market development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/vita_dao

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds4 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VitaDAO